bryostatin-1


Also found in: Medical.

bryostatin-1

[¦brī·ə‚stat·ən ′wən]
(pharmacology)
A polyketide isolated from the bryozoan Bugula neritina that has both anticancer and immune modulating activity.
References in periodicals archive ?
The Company expects to initiate a Phase 2b trial of bryostatin-1 in approximately 150 patients with moderately severe to severe Alzheimer's disease later this year.
Chronic exposure to bryostatin-1 increases the radiosensitivity of U937 leukaemia cells ectopically expressing Bcl-2 through a non-apoptotic mechanism.
For example, Figure 3 shows a MALDI-MS analysis of a pentanol extract of sediment from the same ecosystem and illustrates peaks where bryostatin-1 plus [Na.
BRYOSTATIN-1 PLUS CISPLATIN IN TREATING PATIENTS WITH RECURRENT OR ADVANCED CANCER OF THE CERVIX
We have also discovered that bryostatin-1 synergizes with Histone Deacetylases (HDAC) inhibitors such as valproic acid to antagonise HIV-1 latency.
Drugs Profiles discussed in this report includes acamprosate calcium, basimglurant, Bryostatin-1, cercosporamide, CX-929, Drugs to Inhibit mGluR5 for Fragile X Syndrome, flindokalner, gaboxadol, ganaxolone, Metadoxine ER, minocycline, NNZ-2591, SEL-203, Small Molecule for FXTAS, Small Molecule to Activate Epsilon PKC for Fragile X Syndrome, Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome, Small Molecules to Agonize 5-HT7 for Fragile X Syndrome, Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome, SRT-278 and trofinetide.
This activation and therapeutic response can be achieved by injecting bryostatin 1 directly into chronically inflamed tissues, treating the skin with bryostatin-1, or perfusing organs with bryostatin-1 prior to transplantation and cold storage.
In addition, to the collaboration noted above Neurotrope also has a world-wide, exclusive license agreement with the Icahn School of Medicine at Mount Sinai located in New York City to utilize its proprietary information and data package for the use of bryostatin-1 in the treatment of Niemann-Pick type C Disease, a rare disease, mostly of children who are afflicted with Alzheimer-like symptoms.
Moving Bryostatin-1 from the lab to the clinic for the treatment of pulmonary hypertension:
In addition, Neurotrope has a world-wide, exclusive license agreement with the Icahn School of Medicine at Mount Sinai located in New York City to utilize its proprietary information and data package for the use of bryostatin-1 in the treatment of Niemann-Pick Type C Disease, a rare disease, mostly of children who are afflicted with Alzheimer-like symptoms.
Therapeutic candidates included in this analysis: AG-858, AP23573, Avastin, Atragen, BAY 43-9006, Bryostatin-1, Campath, Ceplene, CEP-701, Clofarabine, Cloretazine, Decitabine, FK228, Flavopiridol, Genasense, Gleevec, GVAX, Mylotarg, Multiferon, OSI-461, Phenoxodiol, pentostatin, PEG-Interferon, PKC412, PTK787, Revlimid, Rituxan, SU5416, SCH 54031, Sarasar, Triapine, Tezacitabine, Troxacitabine, Trisenox, valspodar, Velcade, Zamyl, Zarnestra, Xcytrin, XL999
In each company profile the data is divided according to several different sections and subsections:- General information - Collaborations and alliances - Drug development pipeline (drug name, indications, developmental stages, effects of drugs, mechanism of actions, targets, - combinatory treatments, general comments) - Related patents Some of the drugs included in the report:AG-858, AP23573, Avastin, Atragen, BAY 43-9006, Bryostatin-1, Campath, Ceplene, CEP-701, Clofarabine, Cloretazine, Decitabine, FK228, Flavopiridol, Genasense, Gleevec, GVAX, Mylotarg, Multiferon, OSI-461, Phenoxodiol, pentostatin, PEG-Interferon, PKC412, PTK787, Revlimid, Rituxan, SU5416, SCH 54031, Sarasar, Triapine, Tezacitabine, Troxacitabine, Trisenox, valspodar, Velcade, Zamyl, Zarnestra, Xcytrin, XL999